Symphogen A/S - Company Profile

Powered by

All the data and insights you need on Symphogen A/S in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Symphogen A/S Strategy Report

  • Understand Symphogen A/S position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Symphogen A/S: Overview

Select Item

Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. The company has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. It has offices in Denmark and New Jersey, the US. Symphogen is headquartered in Ballerup, Denmark.

 Gain a 360-degree view of Symphogen A/S and make more informed decisions for your business Gain a 360-degree view of Symphogen A/S and make more informed decisions for your business Find out more
Headquarters Denmark
Address Pederstrupvej 93, Ballerup, 2750
Website www.symphogen.com
Telephone 45 45 265050
No of Employees 95
Industry Pharmaceuticals and Healthcare
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Symphogen A/S premium industry data and analytics

30+

Pipeline Drugs

Identify which of Symphogen A/S’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Clinical Trials

Determine Symphogen A/S go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

8

Catalyst Calendar

Proactively evaluate Symphogen A/S’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Investigators

Review investigator profiles and find information on trial contacts across Symphogen A/S, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Symphogen A/S’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline SymSelect
Sym004 - Metastatic Colorectal Cancer Sympress
Sym021 - Solid Tumors Symplex
XYZ
XYZ
XYZ
Understand Symphogen A/S portfolio and identify potential areas for collaboration Understand Symphogen A/S portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Symphogen A/S Bavarian Nordic AS Zealand Pharma AS CytoVac AS 2cureX ApS
Headquarters Denmark Denmark Denmark Denmark Denmark
City Ballerup Hellerup Soeborg Horsholm Copenhagen
State/Province - - - - Greenland
No. of Employees 95 1,351 249 5 -
Entity Type Private Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Claude Bertrand Chairman Executive Board - -
Christophe Thurieau Chief Executive Officer; Director Executive Board 2020 -
Rikke Bolding Jensen Head - CMC Biologics Senior Management - 54
Lisbet Loschenkohl Head - People and Facility; Senior Vice President - People & Facility Senior Management - -
Karin Garre General Manager - Head-Symphogen A/S Senior Management 2020 66
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Symphogen A/S key executives to enhance your sales strategy Gain insight into Symphogen A/S key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward